rifalazil Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Rifalazil is an antibiotic substance that kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil is used as a treatment for many different diseases. The most common are Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB). Using rifalazil and the effects that coincide with taking rifalazil for treating a bacterial disease vary from person to person, as does any drug put into the human body. Food interactions and genetic variation are a few causes for the variation in side effects from the use of rifalazil. Its development was terminated in 2013 due to severe side effects.   Wikipedia

Chemistry

  • SMILES: CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4C(=O)C(=C5Oc6cc(cc(O)c6N=C5c4c3C2=O)N7CCN(CC(C)C)CC7)NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C
  • InChIKey: UEFHFKKWYKVLDC-HTQYORAHSA-N
  • Mol. Mass: 941.09
  • ALogP: 6.43
  • ChEMBL Molecule:
    rifalazil  
More Chemistry

Pharmacology

Alternative names

3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin | 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin | abi1648 | abi 1648 | abi-1648 | benzoxazinorifamycin | krm 1648 | krm-1648 | rifalazil | rifamycin viii, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo-

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Cerebrovascular Disorders (Phase 2)

Chlamydia (Phase 2)

Coronary Artery Disease (Phase 2)

Intermittent Claudication (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue